Study puts Jardiance in hot pursuit of AZ’s Farxiga in heart...

The FDA’s approval of AstraZeneca’s SGLT2 inhibitor Farxiga in heart failure was a first for the class, but Boehringer Ingelheim and Eli Lilly are closing the gap with a positi

FDA fast-tracks Lilly/Boehringer’s Jardiance in chronic kidn...

Boehringer, Lilly start acute heart failure trial with Jardi...

Diabetes drug Jardiance gains landmark cardiovascular approv...

Lilly and Boehringer Ingelheim will now be able to promote their drug Jardiance in the US as a way for diabetes patients to reduce their risk of having a heart attack or stroke.

New drugs boost Lilly in Q1 as company hopes for turnaround ...

New drugs from Eli Lilly have produced a strong showing in the first quarter, in what could be a key year for a company still recovering from patent expiry of its former blockbuster antidep